| Terrance Matthew Kane, MD | |
|
1700 Medical Center Pkwy, Murfreesboro, TN 37129-2245 | |
| (615) 396-4100 | |
| Not Available |
| Full Name | Terrance Matthew Kane |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 9 Years |
| Location | 1700 Medical Center Pkwy, Murfreesboro, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336602549 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 65241 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Thomas Rutherford Hospital | Murfreesboro, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Havely Springs Physician Services Pc | 3678934726 | 72 |
News Archive
A payment system that provides financial incentives for hospitals that reduce health-care costs for Medicare patients did not lower costs as intended, according to a new study led by Washington University School of Medicine in St. Louis.
NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.
A new study published on the preprint server bioRxiv* in October 2020 describes the gap frequencies and positions in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and a set of alternative primers with a sequencing scheme to provide better genomic coverage and quality.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
› Verified 3 days ago
| Entity Name | Saint Thomas Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437194669 PECOS PAC ID: 1557269354 Enrollment ID: O20031230000470 |
News Archive
A payment system that provides financial incentives for hospitals that reduce health-care costs for Medicare patients did not lower costs as intended, according to a new study led by Washington University School of Medicine in St. Louis.
NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.
A new study published on the preprint server bioRxiv* in October 2020 describes the gap frequencies and positions in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and a set of alternative primers with a sequencing scheme to provide better genomic coverage and quality.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
› Verified 3 days ago
| Entity Name | Havely Springs Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710494174 PECOS PAC ID: 3678934726 Enrollment ID: O20230804002770 |
News Archive
A payment system that provides financial incentives for hospitals that reduce health-care costs for Medicare patients did not lower costs as intended, according to a new study led by Washington University School of Medicine in St. Louis.
NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.
A new study published on the preprint server bioRxiv* in October 2020 describes the gap frequencies and positions in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and a set of alternative primers with a sequencing scheme to provide better genomic coverage and quality.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Terrance Matthew Kane, MD 1700 Medical Center Pkwy, Murfreesboro, TN 37129-2245 Ph: (615) 396-4100 | Terrance Matthew Kane, MD 1700 Medical Center Pkwy, Murfreesboro, TN 37129-2245 Ph: (615) 396-4100 |
News Archive
A payment system that provides financial incentives for hospitals that reduce health-care costs for Medicare patients did not lower costs as intended, according to a new study led by Washington University School of Medicine in St. Louis.
NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.
A new study published on the preprint server bioRxiv* in October 2020 describes the gap frequencies and positions in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and a set of alternative primers with a sequencing scheme to provide better genomic coverage and quality.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
› Verified 3 days ago
Peter Meadows, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 Fax: 615-396-6751 | |
Dr. Eva Leinart, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 | |
Marco A Jarrett, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 820 N Thompson Ln, Suite 1a, Murfreesboro, TN 37129 Phone: 615-494-4800 Fax: 615-494-4801 | |
Dr. Olayinka Adenike Elesha, M.D. Hospitalist Medicare: May Accept Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 Fax: 615-396-6751 | |
Diana Constanza Kooper, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 | |
Dr. Montianna S Bingham, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 Fax: 615-396-6751 |